Clinical Trial

Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 27, 2024 (before its estimated October 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
The goal of this type of clinical trial study is to evaluate the safety and efficacy of Surufatinib combined with Carboplatin/Paclitaxel and Surufatinib combined with Olaparib as first-line and maintenance therapy for newly diagnosed high-risk ovarian cancer
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-05-26; most recent amendment 2024-11-26.
Trial Details
NCT Number NCT06437353
Lead Sponsor Anhui Provincial Cancer Hospital
Collaborators: Hutchison Medipharma Limited
Conditions Ovarian Cancer
Enrollment 74 participants
Start Date 2024-05-25
Primary Completion 2025-10-30 (estimated)
Study Completion 2027-10-30 (estimated)
Updated on ClinicalTrials.gov 2024-11-27